�According to Millennium
Research Group's (MRG) US Markets for Transcatheter Embolization and
Occlusion Devices 2008 account, embolization particle therapies such as
radioembolization spheres ar increasingly beingness used to treat liver
cancer. Over the side by side five eld, these radioembolization procedures are
expected to increase at a compound annual growth rate of almost 20%, as a
result of increased reimbursement coverage and adoption of these techniques
at the institution degree. Introduction of radioembolization spheres to a
facility, however, is not a elementary process, requiring a co-ordinated effort
by the physicians and the administration of a granted institution.
Traditionally, liver crab is treated by surgical resection of tumors
or liver transplantation. Many tumors, however, are not suited for
resection; and liver transplants are infrequent. Chemotherapy with
cytotoxic drugs can be victimized in cases where operating room is contraindicated;
however, it is an extremely arduous process for the patient to brave.
Alternatively, liver-directed particle embolization is a minimally invasive
procedure that employs catheter-based techniques to deliver particle
therapies that inhibit rakehell flow to the inoperable tumor. In addition,
these embolization particles can be combined with chemotherapeutic drugs or
radioactive components to better target the liver, allowing patients safer,
less invasive crab treatment.
"Unlike systemic chemotherapy, which affects the whole body,
liver-directed therapies allow for a stronger, more targeted treatment of
the cancer, resulting in shorter hospital girdle and fewer complications,"
says Darren Navarro, Senior Analyst at MRG. "As more clinical evidence is
released supporting device efficacy, radioembolization spheres will
increasingly be accepted by physicians, institutions, and private insurance
providers as a viable treatment option for inoperable tumors of the liver."
The US Markets for Transcatheter Embolization and Occlusion Devices
2008 report includes coverage of manufacture competitors such as
Biocompatibles, BioSphere Medical, Boston Scientific, Cook Medical, Cordis,
ev3, MDS Nordion, MicroVention, Micrus Endovascular, Sirtex Medical, and
Terumo Medical.
About Radioembolization Spheres
Radioembolization spheres are currently used to treat hepatic cellular
carcinoma (HCC) and metastatic colorectal liver crab in the US. HCC is a
primary liver cancer that originates in the liver, and is often joined to
hepatitis B, hepatitis C, and liver cirrhosis, whereas metastatic
colorectal liver cancer is a secondary cancer that forms in the intestine and
moves to the liver.
About Millennium Research Group
Millennium Research Group (http://www.MRG.net), a Decision Resources,
Inc. company (http://www.DecisionResources.com), is the global authority on
aesculapian technology market place intelligence and the leading provider of
strategic information to the health forethought sector. The company provides
specialized industry expertise through published reports, ongoing
Marketrack(TM) projects, and customized solutions.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
Millennium Research Group
http://www.mrg.net
More info
Sunday, 7 September 2008
Subscribe to:
Posts (Atom)